In breve
Clinical trials investigating Liquid Paraffin are studying its role in skin care for children with atopic dermatitis, also called eczema. These trials mainly look at whether moisturiser-based treatment can help prevent relapse and how well it works compared with reference creams. The focus is on children and their parents or legal guardians.
Punti chiave
- Clinical trials investigating Liquid Paraffin are focused on skin care in children with atopic dermatitis, also called eczema. The main study in the source data is a Phase 3 interventional trial with 270 participants. It looks at whether a newly developed moisturiser can prevent eczema relapse better than a reference cream. The primary outcome is relapse of atopic eczema, measured with a hazard ratio. Relapse is defined as a worsening that needs stronger treatment in the study area, and the date is recorded in an eDiary and checked by the investigator.
Trial overview
The source data includes one interventional study investigating Liquid Paraffin in the setting of childhood eczema. This study is a Phase 3 trial and is marked as Completed. The planned enrollment was 270 participants.
Condition and target population
The condition studied is atopic dermatitis, also called eczema. The trial is focused on children, and the brief summary says the goal is to prevent eczema relapse in children with AD compared with a reference cream.
Study design and treatment groups
The study compares a newly developed moisturiser strategy with a reference cream. The listed topical products include Essex, Advantan® 0,1% Creme, Linola Fett, ECURAL ® Fettcreme, 1 mg/g Creme, and Miniderm Duo 20 mg/g + 200 mg/g kräm. These were given topically, which means they were applied to the skin.
Because the trial is interventional, researchers assigned study treatments and then watched what happened over time. The main question was whether the moisturiser approach could better prevent relapse than the comparison cream.
Main outcome measured
The primary outcome is relapse of atopic eczema, measured as a hazard ratio. A relapse is defined as an episode that, from the participant’s or parent’s or legal guardian’s view, requires escalation of treatment in the study area. The date of relapse is recorded in an eDiary and then confirmed by the investigator.
In simple terms, the study is not only asking whether the skin gets better, but also whether it stays better for longer. This makes the trial especially important for families who want to reduce repeated eczema flare-ups.
What the trial is trying to show
The brief summary says the purpose is to demonstrate superiority of a newly developed moisturiser in preventing eczema relapse in children with AD compared with a reference cream. In clinical research, “superiority” means the new approach is being tested to see if it works better than the comparison treatment.
This kind of trial helps researchers understand whether a skin-care strategy can lower the chance that eczema comes back after improvement. The study also shows how relapse can be tracked in a structured way using patient or caregiver reports and investigator confirmation.
What this means for patients and families
For families, the most important point is that the trial is about preventing relapse, not just treating a single flare-up. The children in the study were followed so researchers could see whether the treatment kept eczema under control for longer.
The trial used clear outcome tracking, which means the study team looked for a defined worsening of eczema and recorded when it happened. This helps make the results easier to compare between treatment groups and more useful for future care decisions.